[
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=71c4d856e14cdbfa3a1767fa9c7b286c7f9ef2049f78d9d2b5f095598cfe977c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750698780,
      "headline": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "id": 135612517,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=71c4d856e14cdbfa3a1767fa9c7b286c7f9ef2049f78d9d2b5f095598cfe977c"
    }
  },
  {
    "ts": null,
    "headline": "FDA Extends INCY's Application for Opzelura Label Expansion",
    "summary": "FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.",
    "url": "https://finnhub.io/api/news?id=b1b9a8a48aca957e3526b720e87aa286be27594cd256a5b9ce783e84e9ee8a54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750686780,
      "headline": "FDA Extends INCY's Application for Opzelura Label Expansion",
      "id": 135482536,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.",
      "url": "https://finnhub.io/api/news?id=b1b9a8a48aca957e3526b720e87aa286be27594cd256a5b9ce783e84e9ee8a54"
    }
  },
  {
    "ts": null,
    "headline": "Update on FDA Review of Ruxolitinib Cream (Opzelura(R)) for Children Ages 2-11 with Atopic Dermatitis",
    "summary": "WILMINGTON, Del. - Incyte today announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for ruxolitinib cream ), a topical...",
    "url": "https://finnhub.io/api/news?id=a25dfe40475a26966a150b9b5ad49cc67fdaac675033f114e69285c2a4977cd4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750673168,
      "headline": "Update on FDA Review of Ruxolitinib Cream (Opzelura(R)) for Children Ages 2-11 with Atopic Dermatitis",
      "id": 135476617,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "WILMINGTON, Del. - Incyte today announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for ruxolitinib cream ), a topical...",
      "url": "https://finnhub.io/api/news?id=a25dfe40475a26966a150b9b5ad49cc67fdaac675033f114e69285c2a4977cd4"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One",
    "summary": "Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.",
    "url": "https://finnhub.io/api/news?id=4e760033ba4821df79b081935dac0af426335dcaf89076ab9b635b322cd8a901",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750670283,
      "headline": "Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One",
      "id": 135475110,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962515/image_1386962515.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.",
      "url": "https://finnhub.io/api/news?id=4e760033ba4821df79b081935dac0af426335dcaf89076ab9b635b322cd8a901"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call",
    "summary": "Incyte’s first quarter was marked by significant commercial momentum and robust top-line growth, leading to a positive market reaction. Management attributed the results to strong demand for Jakafi and Opselura, the initial sales contribution from recently launched Niktimvo, and continued expansion in dermatology and hematology-oncology portfolios. CEO Herve Hoppenot emphasized that “Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, successful l",
    "url": "https://finnhub.io/api/news?id=2552ce52eca0cc13d23de2a36b5af1cf5a88bc438cdda3415222974b381445b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750652373,
      "headline": "5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call",
      "id": 135482537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte’s first quarter was marked by significant commercial momentum and robust top-line growth, leading to a positive market reaction. Management attributed the results to strong demand for Jakafi and Opselura, the initial sales contribution from recently launched Niktimvo, and continued expansion in dermatology and hematology-oncology portfolios. CEO Herve Hoppenot emphasized that “Q1 2025 puts us on a great trajectory for long-term growth with the continuous expansion of Apteloa, successful l",
      "url": "https://finnhub.io/api/news?id=2552ce52eca0cc13d23de2a36b5af1cf5a88bc438cdda3415222974b381445b2"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=83b1c6018ede56bff622b4187ef63d32c2ba2032da387a6c4e2f1cdfb1067fe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750649501,
      "headline": "Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks",
      "id": 135482107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=83b1c6018ede56bff622b4187ef63d32c2ba2032da387a6c4e2f1cdfb1067fe4"
    }
  }
]